Alucent Biomedical Closes $35 Million Series B Financing

Represented Alucent Biomedical, Inc. in its $35 million Series B offering.  The round was led by Philips North America, with Alumend (an existing investor and affiliate of Avera Health) and Fresenius also participating.

Alucent Biomedical is a privately held medical technology company headquartered in Salt Lake City, Utah. It was founded by Alumend to develop and market products using Natural Vascular Scaffolding (NVS) technology. NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.